Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data

Table 6 Risk factors for haemoglobinuria after treatment, multivariable logistic regression model with a random intercept for study site

	N	n	AOR	95% CI	P-value
G6PD status
Normal	2038	32	1.00
Deficient	141	20	2.30	1.15, 4.60	0.018
Dose of PQ^a (per 0.1 mg/kg)	2179	52	1.36	1.08, 1.72	0.010
Hyperparasitaemia^b
No	2046	45	1.00
Yes	133	7	3.92	1.38, 11.12	0.010

N number evaluated, n number with haemoglobinuria
^aAOR = 2.47, 95% CI 1.25–4.89, P-value = 0.009, for comparison between target 0.25 mg/kg primaquine dose and no primaquine arms
^bDefined as parasitaemia > 100,000/μL; compared to patients with lower parasitaemia (n = 1468), no detectable (n = 523) or unknown parasitaemia (n = 55) in study participants who were malaria-positive or gametocytaemic at screening

ISSN: 1741-7015